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Phospholipase C- isozymes that are activated by G
protein-coupled receptors (GPCR) and heterotrimeric G
proteins carry a PSD-95/Dlg/ZO-1 (PDZ) domain binding
motif at their C terminus. Through interactions with
PDZ domains, this motif may endow the PLC- isozyme
with specific roles in GPCR signaling events that occur
in compartmentalized regions of the plasma membrane.
In this study, we identified the interaction of PLC-3
with Shank2, a PDZ domain-containing multimodular
scaffold in the postsynaptic density (PSD). The C termi-
nus of PLC-3, but not other PLC- isotypes, specifically
interacts with the PDZ domain of Shank2. Homer 1b, a
Shank-interacting protein that is linked to group I
metabotropic glutamate receptors and IP3 receptors,
forms a multiple complex with Shank2 and PLC-3. Im-
portantly, microinjection of a synthetic peptide specifi-
cally mimicking the C terminus of PLC-3 markedly
reduces the mGluR-mediated intracellular calcium re-
sponse. These results demonstrate that Shank2 brings
PLC-3 closer to Homer 1b and constitutes an efficient
mGluR-coupled signaling pathway in the PSD region of
neuronal synapses.
Phosphoinositide-specific phospholipase C (PLC)1 plays a
pivotal role in transmembrane signaling. In response to vari-
ous extracellular stimuli, such as numerous hormones, neuro-
transmitters, metabolic products, and growth factors, PLC cat-
alyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate
(PIP2), thereby generating messengers, diacylglycerol and ino-
sitol 1,4,5-trisphosphate (IP3) (1, 2). Mammalian PLC isozymes
have been classified into five types: PLC-, PLC-, PLC-,
PLC-, and PLC- (3–6). Immunohistological studies have
shown that each isotype has a unique distribution pattern in
the brain. PLC-1 is highly expressed in the cerebral cortex
and hippocampus, while PLC-4 is enriched in the cerebellum.
PLC-3 is expressed throughout the brain (7, 8). These findings
suggest that each PLC- isotype may have a distinct role.
Amino acid sequence analysis has shown that PLC- iso-
types share a consensus sequence (X(S/T)X(V/L)-COOH) known
as the postsynaptic density (PSD)-95/disc large/ZO-1 (PDZ)
domain binding motif. PDZ domains exist in a large number of
multifunctional proteins that mediate protein-protein interac-
tions at highly specialized submembranous sites, such as the
postsynaptic density and cellular junctions (9–11). The
postsynaptic density is a macroscopic submembranous multi-
protein complex within the dendritic spines and contains a
variety of scaffolding and signaling proteins. Shank/ProSAP, a
core component of the PSD, is a multimodular protein (200
kDa) that contains various domains for protein interactions
including ankyrin repeats, an SH3 domain, a PDZ domain, a
long proline-rich region, and a SAM domain (12–15). The PDZ
domain of Shank interacts with the GKAP/SAPAP family of
synaptic scaffold proteins. This demonstrates that the Shank
family of multidomain proteins (Shank1/2/3) plays an impor-
tant role in the organization and maintenance of the PSD (16).
The metabotropic glutamate receptor (mGluR) triggers in-
tracellular signaling events by activating PLC- through the
Gq family (17, 18). mGluR is known to be important in defin-
ing the efficacy of mGluR coupling to PLC- (19, 20). In addi-
tion, the Homer proteins, a family of adaptor proteins found at
excitatory synapses, interact with mGluR and functionally link
to the receptor for IP3 generated by PLC (21–23). This finding
led us to postulate that the Homer protein may take part in the
signal pathway between membrane mGluR and PLC.
In this study, we identified Shank2 as a PLC-3-interacting
protein. Shank2 specifically interacts with the C terminus of
PLC-3 but not with other isotypes. Furthermore, Homer 1b
clusters the complexes of PLC-3 and Shank2. Importantly,
disrupting the PLC-3-Shank2 interaction by injection with
synthetic C-terminal heptapeptide of PLC-3 reduced the
mGluR-induced intracellular calcium signal. These results sug-
gest that the complex of PLC-3, Shank2 and Homer 1b may
participate in organizing the molecules involved in PLC-3-
mediated signaling in the PSD.
EXPERIMENTAL PROCEDURES
Yeast Two-hybrid System—Yeast two-hybrid screening was per-
formed as described previously (24). pBHA (LexA fusion vector) carry-
ing DNA oligomers encoding C-terminal heptapeptides of PLC- 3 were
used as the bait in the screening of a rat brain cDNA library in which
the cDNAs were inserted into the activation domain of GAL4 in
pGAD10 (Clontech, Palo Alto, CA). We screened 1.5  106 primary
transformants for interacting proteins. Clones specifically interacting
with the bait were identified by His growth and X-gal activity assays.
The plasmids of positive clones were sequenced, and the sequences were
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compared with sequences in the data bank using the National Center
for Biotechnology Information (NCBI) BLAST system.
Plasmid Constructs—To express the glutathione S-transferase (GST)
fusion form of the C-terminal region of PLC-3 in Escherichia coli, the
cDNA of C-terminal 337 amino acids was amplified by PCR with prim-
ers 5-GCGAATTCCAGCAAGGCTCACAGCTC-3 and 5-GCCTC-
GAGTCAAAGCTGGGTGTTTTCC-3. The resultant PCR product was
inserted as an EcoRI/XhoI fragment into pGEX4T-1 (Amersham Bio-
sciences). To express green fluorescent protein (GFP)-tagged PLC-3 in
mammalian cells, PCR products using appropriate primers were di-
gested with EcoRI/SmaI and then ligated into pEGFP-C1. The cDNA of
Shank2 was kindly provided by M. Sheng from the Massachusetts
Institute of Technology (25). To express Myc-tagged Shank2 in mam-
malian cells, the cDNAs of whole Shank2 and PDZ domain-deleted
Shank2 amplified by PCR were digested with SmaI/SalI, and then
inserted into EcoRV/XhoI-digested pCDNA3.1/Myc-HisA. The GST-
fused PDZ domain of Shank2 was generated by subcloning the SmaI/
XhoI insert of amino acids 37–140 into pGEX4T-3. The cDNA of Homer
1b was isolated from the rat brain cDNA library by PCR using the sense
primers 5-GCGAATTCATGGGGGAACAACCTATC-3 and the anti-
sense primers of 5-ACGCGTCGACTCATTTAATCATGATTGCTG-3.
The GST-fused Homer 1b was generated by subcloning the EcoRI/SalI
inserts into pGEX4T-1. We also constructed the HA-tagged Homer 1b
gene by subcloning the inserts into the EcoRI/SalI sites of pCDNA3-HA,
a HA epitope gene-containing plasmid.
Expression in COS7 Cells and Coimmunoprecipitation—COS7 cells
were cultured in Dulbecco’s modified Eagle’s medium supplemented
with 50 international units/ml penicillin, 50 g/ml streptomycin, and
10% fetal bovine serum in a 5% CO2, 95% air incubator at 37 °C. The
cDNAs for one of the PLC- isotypes carrying an N-terminal FLAG-
epitope tag, and either the wild-type or PDZ-deleted form of Shank2
with a C-terminal Myc epitope tag, were co-expressed in the cells by
transient transfection using Lipofectamine (Invitrogen, Life Technolo-
gies, Inc.). After 36 h, the transfected cells were harvested in lysis buffer
(20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.1 mM
phenylmethylsulfonyl fluoride, 5 g/ml aprotinin, and 1 M pepstatin).
The lysates were centrifuged at 15,000  g for 15 min at 4 °C, and 500
g of the clarified lysate were incubated with anti-FLAG antibody
precoupled to protein A-Sepharose for 3 h at 4 °C for immunoprecipi-
tation. The immune complexes were collected by centrifugation (3 min
at 3000  g), washed four times with lysis buffer, and denaturated by
heating in SDS sample buffer. Proteins were separated by 8% SDS-
PAGE. The separated proteins were then transferred to nitrocellulose
membranes (Schleicher & Schuell BioScience, Keene, NH). Membrane
blocking to prevent nonspecific binding was done with TTBS buffer (10
mM Tris-HCl (pH 7.6), 150 mM NaCl, 0.1% Tween 20) containing 5%
skim milk powder. The blocked membranes were then incubated with
the appropriate antibodies for 4 h at room temperature, after which
they were washed and incubated with horseradish peroxidase-linked
secondary antibody for 1 h at room temperature, washed four times in
TTBS buffer, and developed using horseradish peroxidase-dependent
chemiluminescence (ECL) (Amersham Biosciences).
For the coimmunoprecipitation assay with synaptosome, the synap-
tosomal fraction (P2) was extracted in 1% deoxycholic acid and dialyzed
overnight into 0.1% Triton X-100, 50 mM Tris (pH 7.4). Concurrently, 2
g of each antibody was preincubated overnight with 10-l bed volume
of protein A-agarose. After centrifugation at 100,000  g for 1 h, 100 g
of extract was incubated with antibody-protein A in 100 l of 0.1%
Triton X-100, 50 mM Tris (pH 7.4) for 2 h at 4 °C. The pellets were
washed four times with 1 ml of incubation buffer, and bound proteins
were analyzed by immunoblotting as indicated antibodies, including IP3
receptor (26).
Expression and Purification of GST Fusion Proteins—Recombinant
proteins were expressed in the E. coli strain BL21 containing the
appropriate cDNA constructs. Expression was induced by isopropyl--
D-thiogalactopyranoside (0.1 mM) for 4 h at 25 °C. Subsequently, the
cells were pelleted and sonicated in lysis buffer. The soluble fraction,
after centrifugation at 15,000  g for 20 min at 4 °C, was incubated
with glutathione-Sepharose 4B (Amersham Biosciences) for 3 h at 4 °C
and washed four times with ice-cold lysis buffer.
Pull-down Assay—COS7 cells transiently expressing the PLC- iso-
types or Shank2 were lysed with lysis buffer and centrifuged. The
lysates (500 g) were then incubated with 5 g of the GST fusion
proteins immobilized on glutathione-Sepharose beads at a final lysis
buffer volume of 1 ml for 2 h at 4 °C. The protein complexes were
collected by centrifugation and washed with lysis buffer, followed by
boiling in SDS sample buffer. Proteins were resolved by SDS-polyacryl-
amide gel electrophoresis and immunoblotted.
Transfection and Clustering in COS7 Cells—COS7 cells were trans-
fected with a combination of appropriate plasmids, using the Lipo-
fectamine method (Invitrogen, Life Technologies, Inc.) on poly-L-lysine-
coated coverslips. 24 h after transfection, the cells were fixed in 3.7%
(w/v) paraformaldehyde for 10 min at 37 °C. The fixed cells were
washed with PBS and incubated in blocking buffer (1% goat serum in
PBS containing 0.2% Triton X-100) at 4 °C for 1 h. Subsequently, the
cells were incubated with anti-Shank2 antibody (1 g/ml) or anti-HA
antibody (2 g/ml) overnight at 4 °C. After washing three times with
PBS containing 0.05% Triton X-100 (10 min each), the cells were incu-
bated with secondary antibodies: either rhodamine-conjugated anti-
rabbit or anti-mouse antibody. After washing three times with PBS
containing 0.05% Triton X-100, the slides were mounted and examined
by fluorescence microscopy (Nikon, Inc., Melville, NY).
Immunocytochemistry on Cultured Hippocampal Neurons—Primary
cultured rat hippocampal neuron prepared as described previously (28).
In brief, hippocampus was isolated from rat embryo (20-day gestation),
dissociated, plated on poly-L-lysine-coated glass coverslips, and then
cultured in MEM with 10% horse serum. After 4 days in culture, the
medium was replaced with MEM supplemented with N2 supplement, 1
mg/ml of ovalbumin, 1 M pyruvate, and 5 M cytosine arabinoside,
cultured for 1 week. For immunofluorescence microscopy, the cultured
cells were washed with phosphate-buffered saline, fixed with 4%
paraformaldehyde in phosphate-buffered saline for 1 h, washed with
solution A (20 M phosphate buffer (pH 7.2), and 0.45 M NaCl), and then
treated with solution containing 20 mM Tris (pH 7.5), 140 mM NaCl,
0.1% Triton X-100, and 20% skimmed milk for 30 min. The samples
were incubated with rabbit anti-PLC- 3 (Santa Cruz Biotechnology.
Inc), mouse anti-Shank2 (25) and rat anti-Homer 1b antibodies (29) for
2 h. The samples were then washed with solution A, and incubated with
fluorescein isothiocyanate-conjugated anti-rabbit, Texas red-conju-
gated anti-mouse, and Cy5-conjugated anti-rat antibodies (Molecular
Probes) for 30 min. After incubation, the samples were washed with
solution A, embedded, and then viewed using a confocal imaging system
(Zeiss LSM 510 Meta, Oberkochen, Germany).
Microinjection of Synthetic C-terminal Heptapeptide of PLC-
Isozymes and Intracellular Calcium Response to mGluR Agonist—Es-
tablished hippocampal cells, HN33 were chosen for microinjection. A
solution was injected into the cells via a glass micropipette attached to a
Microinjector (Eppendorf, Hamburg, Germany). Micropipettes had tip
diameters of less than 1 micrometer. The microinjection buffer solution
consists of 27 mM K2HPO4, 8 mM Na2HPO4, 26 mM KH2PO4. Dextran-
conjugated with TRITCwas dissolved with microinjection buffer and used
as a microinjection marker. In preparation for an injection, a micropipette
was lowered to ensure the micropipette had impaled the cell. Then, by
using a semi-automatic button, peptides were injected into the cell. The
responsiveness of the intracellular calcium level was monitored after
mGluR agonist treatment under a confocal microscope. For the intracel-
lular calcium image, Fluo-3 AM (Molecular Probes) was dissolved (1
mg/ml) in dimethyl sulfoxide and stored at 20 °C until use. Cells were
loaded with 2 l Fluo-3 AM for 40 min at room temperature. After
washing with HBSS buffer, the cells were further incubated for 15 min in
the absence of Fluo-3 AM to completely de-esterify the dye. To exclude the
possible effects of dye loading, we normalized with saponin at the end of
the experiments. To normalize, we measured the residual fluorescence
(Fo) at the end of the experiment, and subtracted from the fluorescence of
experiment conditions (F). To rule out the effect of extracellular calcium,
all injection procedures were done in calcium-free solution. Excitation of
Fluo-3 AM was provided by the 488-nm line of an argon laser, and the
emission range was 515 nm. The confocal pinhole was set to the minimum
opening compatible with a good signal-to-noise ratio. The intracellular
calcium image was detected on an inverted confocal microscope (Zeiss
LSM 510 Meta, Oberkochen, Germany) with an objective (20). The
concentration of the peptides used in our experiment ranged from 10 to 30
mM. Injection pressure and time were adjusted to 100–120 kPa and 0.5 s,
respectively. Estimated intracellular concentration of peptides after injec-
tion came to 100 to 300 nM.
Competition of PLC-3 Binding with Shank by Adding Synthetic
C-terminal Peptide of PLC-3 in Vitro—Subcellular fractions of hip-
pocampal neuron in the rat brain (600 g protein) in 400 l of Nonidet
P-40 lysis buffer were prepared. For immunoprecipitation, Shank anti-
body was incubated with hippocampal homogenate. In addition, various
concentrations of the synthetic C-terminal heptapeptide of each PLC-
isozymes were co-incubated to compete with endogenous PLC-3 and
Shank binding. After incubation for 4 h at 4 °C, immunocomplexes were
separated by incubation with protein-A/G Sepharose. Western blotting
was performed with the PLC-3 antibody by standard procedures and
detected by ECL chemiluminescence.
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Data Analysis—The calcium imaging data are expressed as a
means  S.D. Statistical analysis was carried out using SAS 8.01(SAS
Institute Inc., Cary, NC). A difference was taken as significant if p 
0.05. Comparisons between cells were analyzed using repeated measure
ANOVA (analysis of variance).
RESULTS
Identification of the PLC-3-interacting Protein—The C-ter-
minal heptapeptide (QEENTQL-COOH) of PLC-3 was used as
bait in the yeast two-hybrid assay screening for proteins inter-
acting with PLC-3. One positive clone from a rat brain cDNA
library was obtained and sequenced and found to contain the
N-terminal 360 amino acids of Shank2, which harbors a PDZ
domain. The specificity of the interaction between the C-termi-
nal motif of PLC-3 and the various PDZ domains, including
Shank2 PDZ, was examined using the yeast two-hybrid assay
(Table I). His activity and the -galactosidase responses of the
yeast cells transformed with the PLC-3 motif and the PDZ of
Shank2 were similar to those of the PLC-3 motif and the
PDZ2 of NHERF2, a positive control. No responses were exhib-
ited by transformants of the PDZ domain of PSD-95 or
NHERF1. These results demonstrate that the PLC-3 specifi-
cally interacts with Shank2.
Interaction Domains between PLC-3 and Shank2 in
Vitro—To confirm the interaction between PLC-3 and
Shank2, GST-Shank2 protein was used in a pull-down assay
of COS7 cell lysates transfected with FLAG-PLC-3 or
FLAG-PLC-3C (deleted C-terminal four amino acids, PDZ
binding motif). Full-length PLC-3, but not the deleted mu-
tant, was pulled down by GST-Shank2 (Fig. 1A). Conversely,
Shank2 expressed in COS7 cells was precipitated by the
GST-PLC-3 C-terminal 337 amino acids, but not GST alone
(Fig. 1B).
Specific Interaction of PLC- Isotypes and Shank2 in Vivo—
All PLC- isotypes contain the PDZ binding motif at their C
termini that may enable the PLC-s to associate with the PDZ
domain-containing proteins. To investigate the interaction be-
tween Shank2 and each PLC- isotype, immunoprecipitation
using an anti-FLAG antibody was performed with extracts of
COS7 cells expressing Shank2 and each of the FLAG-tagged
PLC- isotypes. Shank2 was detected in the immunoprecipi-
tates only with FLAG-PLC-3, but not with any of the other
isotypes (Fig. 2A), implying that Shank2 specifically interacts
with PLC-3. To characterize this interaction, the lysates of
COS7 cells co-expressing FLAG-PLC-3 and Myc-Shank2 were
immunoprecipitated with FLAG antibodies. As shown in Fig. 2,
B and C, PLC-3 was co-precipitated with Shank2, whereas the
C-terminally deleted PLC-3 and the PDZ domain-deleted
form of Shank2 were not co-precipitated with Shank2 and
PLC-3, respectively. These results suggest that PLC-3 inter-
acts with the PDZ domain of Shank2 via the C-terminal PDZ
binding motif.
Several reports demonstrate that PDZ domains bind to the
C-terminal four amino acids of the target proteins (11). To
identify critical residues of the PLC-3 C terminus that are
required for the Shank2 interaction, each of the last four amino
acid residues of PLC-3 (NTQL-COOH) were mutated to Ala.
The extracts of COS7 cells co-expressing each FLAG-tagged
PLC-3 mutant and Shank2 were incubated with an anti-
FLAG antibody, and the precipitates were then probed with an
anti-Shank antibody. Substitution of Thr to Ala at the second-
ary amino acid or Leu to Ala at the last position resulted in a
complete loss of Shank2 binding to PLC-3. In contrast, the
substitution of the other residues to Ala had no effect (Fig. 2D).
These results thus indicate that the Thr and Leu residues of
PLC-3 are essential for the interaction with Shank2.
PLC-3 Associates with Homer 1b Through Shank2—Re-
cently, it was reported that Shank1 and Shank3 associate
with the EVH domain of the Homer family (23), and sequence
analysis indicates that Shank2 possesses two similar proline-
rich Homer binding regions. To verify that Shank2 can also
associate with Homer and that Shank2 can link PLC-3 to
Homer 1b, COS7 cells extracts expressing Shank2 and
PLC-3 were used in pull-down assays with GST-Homer 1b.
Extracts of COS7 cells co-expressing Shank2 and Homer 1b
were used for precipitation with the GST-PLC-3 C-terminal
motif. As shown in Fig. 3, A and B, GST-Homer 1b pulled-
down PLC-3 only in the presence of Shank2. Conversely, the
GST-PLC-3 C terminus pulled down Homer 1b only in the
presence of Shank2, suggesting that these three proteins
form a ternary complex.
To further explore the ternary complex of PLC-3, Shank2,
and Homer 1b, immunocytochemistry was performed on COS7
cells expressing these proteins. In triply expressed cells, PLC-
3, Shank2, and Homer 1b were distributed in plaque-like
clusters (Fig. 4A, panels A1 and B1). In a control experiment,
PLC-1 did not colocalize with Shank2 and Homer 1b (Fig. 4A,
TABLE I
Shank2 interacts specifically with the PDZ domain binding
motif of PLC-3
The C-terminal heptapeptide of PLC-3 was tested for its ability to
bind Shank2 in the yeast two-hybrid assay, where it is revealed by the
induction of the yeast reporter genes HIS3 and -galactosidase. HIS
activity (measured as percentage of colonies growing on histidine-lack-
ing medium) was rated as follows: (	60%), (30–60%),
(30%), (no significant growth); -galactosidase activities (time
needed for yeast colonies to turn blue in X-gal filter lift assays at room
temperature) were as follows: (20 min), (20–60 min), (no
detection). PDZ domain of NHERF2 was used as positive control.
pBHA clones pGAD10 clones HIS3 -Gal
C-terminal of PLC-3 (NTQL) pGAD10 alone  
NHERF1 PDZ1  
PSD95 PDZ1  
NHERF2 PDZ2  
Shank2 PDZ  
FIG. 1. Interaction of Shank2 with PLC-3 in vitro. A, PLC-3
interacts with Shank2 through its C-terminal PDZ binding motif. Ex-
tracts of COS7 cells expressing FLAG-tagged wild type or the C-termi-
nally deleted form of PLC-3 were precipitated with GST-Shank2 PDZ
domain, and the precipitated proteins were detected with anti-FLAG
antibody. The first two lanes (Lysate) were directly loaded with each
transfected cell lysate (5% of input). B, interaction of GST-PLC-3 C
terminus with Shank2. Conversely, the extracts of COS7 cells express-
ing Shank2 were precipitated with GST- PLC-3 C-terminal (337 amino
acids). The precipitates were detected with anti-Shank antibody. The
first lane (Lysate) was loaded with the transfected cell lysate (5%
of input).
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panel C1). These results are consistent with the lack of inter-
action between PLC-1 and Shank2 in coimmunoprecipitation
assays (Fig. 2A). When C-terminal-deleted PLC-3 (Fig. 4A,
panel D1) or PDZ-domain-deleted Shank2 (Fig. 4A, panel E1)
were co-expressed with the other proteins, PLC-3 did not
exhibit any clustering with Shank2. On the other hand, both
the wild-type and the PDZ-deleted form of Shank2 were clus-
tered with Homer 1b, consistent with the previous finding that
the Homer binding region resides in the proline-rich region of
Shank2 (29). We further verified the ternary complex of PLC-
3, Shank2, and Homer1 b using freshly isolated hippocampal
cells. Similar with the result of COS7, PLC-3, Shank2, and
Homer 1b were existed as a plaque-like cluster form in these
cells also (Fig. 4B). Taken together, these results suggest that
FIG. 2. Coimmunoprecipitation of
Shank2 and PLC-3 via the PDZ do-
main from cotransfected COS cells. A,
extracts of COS7 cells expressing Shank2
together with one of the PLC- isotypes
(isotypes 1–4) were allowed to immunore-
act with anti-FLAG antibody. The precip-
itates were separated by SDS-polyacryl-
amide gel electrophoresis, and probed
with anti-Shank antibody. Left lanes (ly-
sates) were each loaded with transfected
cell lysates (5% of input). B, PLC-3 in-
teracts with Shank2 through its PDZ
binding motif. The extracts of COS7 cells
expressing Shank2 together with wild-
type or C-terminally deleted FLAG-
PLC-3 were immunoprecipitated using
anti-FLAG antibody. The precipitates
were then analyzed with anti-Shank an-
tibody (upper panel) or anti-FLAG anti-
body (lower panel). The three lanes on the
left (lysates) were directly loaded with
transfected cell lysates (5% of input). C,
extracts of COS7 cells expressing FLAG-
PLC-3 with wild-type or PDZ-deleted
Myc-Shank2 were incubated with anti-
FLAG antibody. The immune complexes
were analyzed with anti-Myc antibody.
The left three lanes (lysates) were each
loaded with transfected cell lysates (5% of
input).D, each residue of the PDZ binding
motif in PLC-3 was mutated in turn to
Ala by the polymerase chain reaction with
mutagenic primers. Extracts of COS7
cells expressing Shank2 with one of the
point-mutated forms of PLC-3 were al-
lowed to immunoreact with anti-FLAG
antibody. The precipitated proteins were
probed with anti-Shank antibody (upper
panel) or anti-FLAG antibody (lower
panel). Left lanes (lysates) were each
loaded with transfected cell lysates (5%
of input).
FIG. 3. Shank2 mediates the association of PLC-3 and Homer 1b. A, GST-Homer 1b interacts with the PLC-3-Shank2 complex. The
extracts of COS7 cells expressing PLC-3 alone, or PLC-3 and Shank2 were incubated with GST-Homer 1b immobilized on glutathione beads.
The precipitates were analyzed using anti-Shank antibody (upper panel) or anti-PLC-3 antibody (lower panel). Left two lanes (Lysate) were loaded
directly with each transfected cell lysates (5% of input) (B). The GST-fused PLC-3 C terminus interacts with the Homer 1b-Shank2 complex.
Extracts of COS7 cells expressing Homer 1b alone, or Homer 1b and Shank2 were incubated with GST-fused PLC-3-C terminus (337 amino acids).
The complexes were analyzed with anti-Shank antibody (upper panel) or anti-HA antibody (lower panel). The two left lanes (lysates) were each
loaded directly with transfected cell lysates (5% of input). HA, hemagglutinin.
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Shank2 mediates the formation of a ternary complex contain-
ing Homer 1b and PLC-3.
Coimmunoprecipitation of Shank2-interacting Proteins in
Brain—Next we determined the in vivo association of Shank2,
PLC-3, Homer 1b, and IP3 receptor. When the P2 fraction of
adult rat brain was immunoprecipitated with Shank2 anti-
body, PLC-3, Homer 1b, and IP3 receptor were coimmunopre-
cipitated, but not with IgG (Fig. 5A). In addition, to determine
whether C-terminal heptapeptide of PLC-3 can compete with
the endogenous PLC-3-Shank2 interaction, we added the syn-
thetic C-terminal peptide of PLC-3 during the immunopre-
cipitation reaction. For immunoprecipitation, we incubated
Shank2 antibody with P2 fraction of adult rat brain. The
amount of coimmunoprecipitated PLC-3 with Shank2 de-
creased by synthetic PLC-3 peptide addition in a dose-depend-
ent manner, whereas the association was unaffected by addi-
tion of C-terminal peptides of other isozymes (Fig. 5B). Taken
together, these results demonstrate that PLC-3 and Shank2
may be distributed to synaptic sites and form a complex
in brain.
Effect of Microinjection of Synthetic PLC-3 C-terminal Hep-
tapeptide on mGluR Agonist-induced Intracellular Calcium Re-
lease—To gain physiological insights into PLC-3 binding with
Shank2, we investigated the effect of this binding on mGluR
agonist-induced intracellular calcium signal. To accomplish
this, we used HN33 hippocampal cells, because these cells
showed an intracellular calcium increase in response to a
mGluR agonist, N-1,3-cyclopentanedicarboxylic acid (ACPD,
20 M). It has been suggested that Shank may cross-link
Homer with the PSD-95 complex in the postsynaptic density
and play a role in the mGluR signaling. Such a linkage has
important implication in the coupling of mGluR receptors to
intracellular calcium pools. Therefore, we hypothesized that
the calcium release responding to the mGluR agonist might be
changed by disrupting Shank2-PLC-3 binding. To test this
hypothesis, we microinjected a synthetic C-terminal heptapep-
tide of PLC-3 into the cytoplasm of the HN33 cells and mon-
itored the calcium signal. As a control, we injected C-terminal
heptapeptides of other PLC- isozymes. Cells injected with
PLC-3 peptide showed a markedly decreased calcium signal
(Fig. 6). Injection with peptides of other PLC- isozymes (PLC-
1, PLC-2, and PLC-4) did not cause any detectable changes
in the calcium signaling. Altogether, we injected 10 cells at a
time and performed three independent experiments. These re-
sults were reproduced in every experiment. To rule out the
involvement of an extracellular calcium effect, we performed
the microinjection procedure under calcium-free buffer
condition.
These results demonstrate that microinjection of the C-ter-
minal peptide of PLC-3 suppresses the mGluR agonist in-
duced calcium release in a dose dependent manner, but C-
terminal peptides of other isozymes have no significant effect.
Taken together, these results demonstrate that the PLC-3-
Shank2 interaction may play an important role in mGluR-
mediated intracellular calcium release.
DISCUSSION
In this report, we identified a modular interaction between
the C terminus of PLC-3 and the PDZ domain of Shank2. In
support of this conclusion, the C-terminal four amino acids of
PLC-3 are required for the interaction with Shank2 (Fig. 1),
and point mutations at the PLC-3 C terminus eliminate the
Shank2 interaction (Fig. 2D). In addition, our data indicate
that Shank2 forms a specific complex with PLC-3, but not
with other PLC- isoforms (Fig. 2A), despite the fact that other
PLC- isoforms also contain the PDZ domain binding motif at
their C termini. These results suggest that PLC- isoforms
may act in different signaling pathways by interacting with
distinct PDZ-containing proteins.
Previously, we had found that NHERF2 specifically interacts
with and enhances the activation of PLC-3 by the muscarinic
receptor (30). However, other isotypes of PLC- barely interact
with NHERF2. With respect to Shank2, the immunoprecipita-
tion analyses performed in the present study demonstrated
that Shank2 specifically interacted with PLC-3, but not with
FIG. 4. Clustering of PLC-3 with Shank2 mediated by Homer
1b requires PDZ domain-mediated interaction. A, clustering of
PLC-3 with Shank2 is mediated by Homer 1b in heterologous cells.
COS7 cells triply transfected with GFP-PLC-3, Shank2, and Homer 1b
were fixed and labeled with anti-Shank antibody (panel A2) or anti-HA
antibody (panel B2). Each protein was visualized as described under
“Experimental Procedures.” COS7 cells triply transfected with GFP-
PLC-1, Shank2, and HA-Homer 1b were fixed and labeled with anti-
Shank antibody (panel C2). COS7 cells were triply transfected with C
terminus-deleted GFP-PLC-3, Shank2 and Homer 1b (panel D), or
GFP-PLC-3, PDZ-domain-deleted Shank2 and Homer 1b (panel E).
Shank2 was visualized using rabbit anti-Shank antibodies and rhoda-
mine-conjugated anti-rabbit secondary antibodies. Merged images are
shown in the panels on the right (panels A3, B3, C3, D3, and E3). B,
localization of PLC-3, Shank2 and Homer 1b in cultured hippocampal
cells. Cultured hippocampal cells were triple immunostained with anti-
PLC-3 (green, upper) and anti-Shank2 (red, middle) and anti-Homer
1b (blue, lower). The images were merged in the bottom panels. Left
panels were imaged at low-resolution (10). Right panels were imaged
at high-resolution (40). Arrowhead indicates the colocalization of tri-
ple complexes.
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the other isotypes. In immunoblot analysis, Shank2 was de-
tected in brain tissues, but NHERF2 was not detected, imply-
ing that each of two PDZ proteins may play a role in PLC-3-
mediated signaling in different tissues. It has been known that
PDZ-containing proteins mediate the clustering of receptors
and signaling molecules and thereby regulate agonist-induced
signal transduction (31). Thus, the signaling through PLC-3
may be spatially regulated in cells via the interaction with
PDZ-containing proteins.
Proline-rich motifs of Shank2 have been shown to interact
with the Homer family, EVH domain-containing proteins (23).
Recently, it has been demonstrated that Homer 1 operates in a
negative feedback loop that regulates the structure and func-
tion of the synapse (32). Homer proteins normally exist in
oligomeric forms and are known to interact with group 1
metabotropic glutamate receptors and the inositol 1,4,5-
trisphosphate receptor, and therefore may be involved in the
cytosolic calcium release by IP3, a product of PLC activation
(22, 27). Given these findings, we propose that Shank2 may
serve as a scaffold for G protein-coupled receptor signaling
cascades in the PSD by forming bridges between the Homer
family and PLC-3. Shank2, and PLC-3 undergo a dramatic
FIG. 5. PLC-3 is coimmunoprecipitated with Shank2 and Homer 1b in the PSD fraction and is disrupted by adding synthetic
PLC-3 C-terminal heptapeptide in vitro. A, extracts of rat hippocampal synaptosomal membranes were immunoprecipitated with anti-Shank
antibodies, or with control immunoglobulin (IgG). Immunoprecipitates were then immunoblotted with anti-PLC-3, Homer 1b and IP3 receptor
antibodies as indicated. The first lane (lysates) was loaded with the immunoprecipitation extract (10% of input). B, competition of the PLC-3
binding with Shank by adding the synthetic C-terminal peptide of PLC-3 in vitro. 600 g of extracts of rat hippocampal synaptosomal membranes
was immunoprecipitated with anti-Shank antibody, while various concentrations of synthetic C-terminal peptides of each PLC- isozyme were
added. Immunocomplexes were analyzed by Western blotting with anti-PLC-3 antibody.
FIG. 6. Microinjection of synthetic C-terminal heptapeptide of PLC-3 suppresses the mGluR agonist-induced intracellular
calcium increase in HN33 cells. The peak increase in fluo-3 fluorescence (F/Fo) in response to 20 M ACPD, mGluR agonist. Isozyme-specific
C-terminal peptides were microinjected into the cells prior to ACPD treatment. The calcium signal was obtained by an image software program
and viewed as a function of time. Results are representative of at least three individual experiments. Solid lines indicate the non-transfected cells
and dotted lines indicate the microinjected cells. p  0.0001.
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re-localization to form plaque-like clusters when they are co-
expressed with Homer 1b. The experiment using deletion mu-
tants of Shank2 or PLC-3 indicates that PLC-3 is recruited
into Shank2/Homer 1b complexes through PDZ domain-medi-
ated interaction.
As previously reported, Shank2 is enriched in the PSD frac-
tions (33). Considering PSD signaling events in neuronal cells
harboring mGluR signaling networks (34), it is believed that
PLC-3 may be involved in mGluR-mediated signaling, and
Homer 1b actually increases mGluR-evoked calcium mobiliza-
tion (29). Up to now, the role of scaffolding proteins in mediat-
ing tyrosine kinase receptors is well characterized (35). How-
ever, much less is known about the scaffolding protein’s role in
calcium signaling. In synapses, PSD-95, Shank, GRIP, and
probably other scaffolds, participate in the assembly of signal-
ing complexes, including the role for calcium signaling. In the
present study, we provided the evidence for the role of the
binding between Shank2 and PLC-3 in mGluR-mediated cal-
cium mobilization. We did not check the direct effect of Shank2
on PLC- activity. Thus, whether mGluR-evoked calcium re-
sponse occurs through recruiting signal molecules to the
mGluR receptor or directly affecting PLC- activity is yet to
be determined.
In conclusion, PLC-3 interacts with Shank2 via the PDZ
binding motif. The isotype-specific interaction of PLC-3 with
Shank2 shows that PDZ-containing proteins allow signaling
molecules to be involved in a specific signaling cascade by
recruiting them to specific compartments. Homer 1b, a type I
mGluR-interacting protein, forms clusters with PLC-3, which
is mediated by Shank2. Upon clustering of the ternary complex
consisting of Homer 1b-Shank2-PLC-3, the spatially re-
stricted signaling complexes in the PSD are made possible.
This finding may lead us to a better understanding of the
activation mechanism of PLC-3 by GPCRs in the PSD of
neuronal cells.
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